In the last three months, 11 analysts have published ratings on Quest Diagnostics DGX, offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 3 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $178.45, a high estimate of $185.00, and a low estimate of $170.00. This upward trend is apparent, with the current average reflecting a 5.03% increase from the previous average price target of $169.90.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Quest Diagnostics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Donnelly | Citigroup | Maintains | Neutral | $185.00 | $185.00 |
| Lisa Gill | JP Morgan | Raises | Neutral | $180.00 | $173.00 |
| Ann Hynes | Mizuho | Raises | Outperform | $178.00 | $177.00 |
| Kevin Caliendo | UBS | Raises | Neutral | $170.00 | $166.00 |
| David Westenberg | Piper Sandler | Raises | Neutral | $180.00 | $165.00 |
| David Macdonald | Truist Securities | Raises | Hold | $182.00 | $172.00 |
| Stephanie Davis | Barclays | Raises | Equal-Weight | $175.00 | $168.00 |
| Michael Cherny | Leerink Partners | Raises | Outperform | $174.00 | $169.00 |
| Erin Wright | Morgan Stanley | Raises | Overweight | $172.00 | $145.00 |
| Derik De Bruin | B of A Securities | Raises | Buy | $182.00 | $179.00 |
| Tycho Peterson | Jefferies | Announces | Buy | $185.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Quest Diagnostics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Quest Diagnostics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Quest Diagnostics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Quest Diagnostics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Quest Diagnostics analyst ratings.
Get to Know Quest Diagnostics Better
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Financial Insights: Quest Diagnostics
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Quest Diagnostics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.39%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.24%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's ROA stands out, surpassing industry averages. With an impressive ROA of 1.36%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below the industry average. With a ratio of 1.05, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
